Publications: SC24 and BRC5

Kerba M, Lourenco RDA, Sahgal A, Cardet RdF, Siva S, Ding K, Myrehaug S, Masucci GL, Brundage M, Parulekar WR. An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared with Conventional Palliative RT for Spinal Metastases (ONLINE). International Journal of Radiation Oncology*Biology*Physics 2024. https://www.sciencedirect.com/science/article/pii/S0360301624000221
 

A multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases were randomized to either 24 Gy/2 stereotactic body radiotherapy (SBRT) or 20 Gy/5 conventional external beam radiotherapy (CRT). The study met its primary endpoint demonstrating superior complete pain response rates (CRR) at 3 months following SBRT (35%) vs CRT (14%). SBRT planning and delivery is resource intensive. Given its benefits an economic analysis was performed to determine the incremental cost-effectiveness of SBRT compared to CRT.

 

SBRT is associated with higher upfront costs compared to CRT. The study shows that, within the Canadian health care system, SBRT with 2 fractions is likely to be cost-effective relative to CRT.

 

 

Stinchcombe TE, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Altorki N. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer (ONLINE). Journal of Clinical Oncology 2024.

 

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.